Advertisement

Sepsis Biomarkers

  • Jean-Louis Vincent
  • Christophe Lelubre
Chapter

Abstract

Accurate and early diagnosis of sepsis is essential to enable rapid initiation of appropriate therapy. Biomarkers can be used to aid in diagnosis, but also to provide an indication of severity and prognosis and of response to treatment. C-reactive protein and procalcitonin are the biomarkers that have been most widely studied in sepsis, but there are many other potential candidates, including CD64 expression, adrenomedullin, sTREM-1, and presepsin. All currently available biomarkers reflect the magnitude of the host response to an aggression and are affected by inflammatory conditions other than sepsis. This lack of specificity makes them more useful to rule out than to rule in infection as a diagnosis. Panels of biomarkers may be better than individual biomarkers to aid diagnosis, but which combinations of biomarkers are likely to be of greatest use remains a matter of ongoing research. Whichever biomarker(s) is used, levels must be interpreted in the context of the full clinical picture and never in isolation.

Keywords

Adrenomedullin Antibiotic CD64 C-reactive protein Infection Procalcitonin Prognosis 

References

  1. 1.
    Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.CrossRefGoogle Scholar
  2. 2.
    Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193:259–72.CrossRefGoogle Scholar
  3. 3.
    Shankar-Hari M, Rubenfeld GD. Understanding long-term outcomes following sepsis: implications and challenges. Curr Infect Dis Rep. 2016;18:37.CrossRefGoogle Scholar
  4. 4.
    Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45:486–552.CrossRefGoogle Scholar
  5. 5.
    Pewsner D, Battaglia M, Minder C, et al. Ruling a diagnosis in or out with “SpPIn” and “SnNOut”: a note of caution. BMJ. 2004;329:209–13.CrossRefGoogle Scholar
  6. 6.
    Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.CrossRefGoogle Scholar
  7. 7.
    Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–71.CrossRefGoogle Scholar
  8. 8.
    Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169–77.CrossRefGoogle Scholar
  9. 9.
    National Institute for Health and Care Excellence. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: Royal College of Physicians; 2009.Google Scholar
  10. 10.
    Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis. 2015;2:ofv098.CrossRefGoogle Scholar
  11. 11.
    Silvestre JP, Coelho LM, Povoa PM. Impact of fulminant hepatic failure in C-reactive protein? J Crit Care. 2010;25:657–12.CrossRefGoogle Scholar
  12. 12.
    Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396–404.PubMedGoogle Scholar
  13. 13.
    Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515–8.CrossRefGoogle Scholar
  14. 14.
    Mofidi R, Suttie SA, Patil PV, et al. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery. 2009;146:72–81.CrossRefGoogle Scholar
  15. 15.
    Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care. 2006;10:R1.CrossRefGoogle Scholar
  16. 16.
    Meisner M, Rauschmayer C, Schmidt J, et al. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med. 2002;28:1094–102.CrossRefGoogle Scholar
  17. 17.
    Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis. 2014;59:1761–7.CrossRefGoogle Scholar
  18. 18.
    Djebara S, Biston P, Fosse E, et al. Time course of CD64, a leukocyte activation marker, during cardiopulmonary bypass surgery. Shock. 2017;47:158–64.CrossRefGoogle Scholar
  19. 19.
    Dimoula A, Pradier O, Kassengera Z, et al. Serial determinations of neutrophil CD64 expression for the diagnosis and monitoring of sepsis in critically ill patients. Clin Infect Dis. 2014;58:820–9.CrossRefGoogle Scholar
  20. 20.
    Wang X, Li ZY, Zeng L, et al. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Crit Care. 2015;19:245.CrossRefGoogle Scholar
  21. 21.
    de Jong E, de Lange DW, Beishuizen A, et al. Neutrophil CD64 expression as a longitudinal biomarker for severe disease and acute infection in critically ill patients. Int J Lab Hematol. 2016;38:576–84.CrossRefGoogle Scholar
  22. 22.
    Marino R, Struck J, Maisel AS, et al. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014;18:R34.CrossRefGoogle Scholar
  23. 23.
    Caironi P, Latini R, Struck J, et al. Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. Chest. 2017;152:312–20.CrossRefGoogle Scholar
  24. 24.
    Simon TP, Martin L, Doemming S, et al. Plasma adrenomedullin in critically ill patients with sepsis after major surgery: a pilot study. J Crit Care. 2017;38:68–72.CrossRefGoogle Scholar
  25. 25.
    Bouchon A, Facchetti F, Weigand MA, et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103–7.CrossRefGoogle Scholar
  26. 26.
    Su L, Liu D, Chai W, et al. Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis. BMJ Open. 2016;6:e010314.CrossRefGoogle Scholar
  27. 27.
    Behnes M, Bertsch T, Lepiorz D, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014;18:507.CrossRefGoogle Scholar
  28. 28.
    Yu H, Qi Z, Hang C, et al. Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis. Am J Emerg Med. 2017;35:835–41.CrossRefGoogle Scholar
  29. 29.
    Matera G, Quirino A, Peronace C, et al. Soluble CD14 subtype-a new biomarker in predicting the outcome of critically ill septic patients. Am J Med Sci. 2017;353:543–51.CrossRefGoogle Scholar
  30. 30.
    Zhang X, Liu D, Liu YN, et al. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015;19:323.CrossRefGoogle Scholar
  31. 31.
    Wu CC, Lan HM, Han ST, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care. 2017;7:91.CrossRefGoogle Scholar
  32. 32.
    Kumar A, Haery C, Paladugu B, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis. 2006;193:251–8.CrossRefGoogle Scholar
  33. 33.
    Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–7.CrossRefGoogle Scholar
  34. 34.
    de Jong PR, Gonzalez-Navajas JM, Jansen NJ. The digestive tract as the origin of systemic inflammation. Crit Care. 2016;20:279.CrossRefGoogle Scholar
  35. 35.
    Ugarte H, Silva E, Mercan D, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27:498–504.CrossRefGoogle Scholar
  36. 36.
    Povoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect. 2005;11:101–8.CrossRefGoogle Scholar
  37. 37.
    Santonocito C, De Loecker I, Donadello K, et al. C-reactive protein kinetics after major surgery. Anesth Analg. 2014;119:624–9.CrossRefGoogle Scholar
  38. 38.
    Povoa P, Coelho L, Almeida E, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care. 2006;10:R63.CrossRefGoogle Scholar
  39. 39.
    Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996–2003.CrossRefGoogle Scholar
  40. 40.
    Castelli GP, Pognani C, Cita M, et al. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med. 2009;37:1845–9.CrossRefGoogle Scholar
  41. 41.
    Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138:1108–15.CrossRefGoogle Scholar
  42. 42.
    Gaini S, Koldkjaer OG, Pedersen C, et al. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006;10:R53.CrossRefGoogle Scholar
  43. 43.
    Ljungstrom L, Pernestig AK, Jacobsson G, et al. Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One. 2017;12:e0181704.CrossRefGoogle Scholar
  44. 44.
    Kapasi AJ, Dittrich S, Gonzalez IJ, et al. Host biomarkers for distinguishing bacterial from non-bacterial causes of acute febrile illness: a comprehensive review. PLoS One. 2016;11:e0160278.CrossRefGoogle Scholar
  45. 45.
    Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123:2043–9.CrossRefGoogle Scholar
  46. 46.
    Grander W, Dunser M, Stollenwerk B, et al. C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest. 2010;138:856–62.CrossRefGoogle Scholar
  47. 47.
    Al-Subaie N, Reynolds T, Myers A, et al. C-reactive protein as a predictor of outcome after discharge from the intensive care: a prospective observational study. Br J Anaesth. 2010;105:318–25.CrossRefGoogle Scholar
  48. 48.
    Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, et al. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect. 2011;77:58–63.CrossRefGoogle Scholar
  49. 49.
    Hong DY, Park SO, Kim JW, et al. Serum procalcitonin: an independent predictor of clinical outcome in health care-associated pneumonia. Respiration. 2016;92:241–51.CrossRefGoogle Scholar
  50. 50.
    Liu D, Su L, Han G, et al. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One. 2015;10:e0129450.CrossRefGoogle Scholar
  51. 51.
    Karlsson S, Heikkinen M, Pettila V, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14:R205.CrossRefGoogle Scholar
  52. 52.
    Ranzani OT, Prada LF, Zampieri FG, et al. Failure to reduce C-reactive protein levels more than 25% in the last 24 hours before intensive care unit discharge predicts higher in-hospital mortality: a cohort study. J Crit Care. 2012;27:525–15.CrossRefGoogle Scholar
  53. 53.
    Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26:331–7.CrossRefGoogle Scholar
  54. 54.
    Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin MOnitoring SEpsis (MOSES) study. Crit Care Med. 2017;45:781–9.CrossRefGoogle Scholar
  55. 55.
    Hoeboer SH, Groeneveld AB. Changes in circulating procalcitonin versus C-reactive protein in predicting evolution of infectious disease in febrile, critically ill patients. PLoS One. 2013;8:e65564.CrossRefGoogle Scholar
  56. 56.
    Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection. 2008;36:213–9.CrossRefGoogle Scholar
  57. 57.
    Lisboa T, Seligman R, Diaz E, et al. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:166–71.CrossRefGoogle Scholar
  58. 58.
    Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J. 2008;32:726–32.CrossRefGoogle Scholar
  59. 59.
    Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013;41:2336–43.CrossRefGoogle Scholar
  60. 60.
    Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93.CrossRefGoogle Scholar
  61. 61.
    Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.CrossRefGoogle Scholar
  62. 62.
    Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66.CrossRefGoogle Scholar
  63. 63.
    Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–74.CrossRefGoogle Scholar
  64. 64.
    de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819–27.CrossRefGoogle Scholar
  65. 65.
    Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177:498–505.CrossRefGoogle Scholar
  66. 66.
    Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck’s Arch Surg. 2009;394:221–6.CrossRefGoogle Scholar
  67. 67.
    Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis: a randomized controlled trial. Am J Respir Crit Care Med. 2014;190:1102–10.CrossRefGoogle Scholar
  68. 68.
    Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176:1266–76.CrossRefGoogle Scholar
  69. 69.
    Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis. 2013;76:266–71.CrossRefGoogle Scholar
  70. 70.
    Chu DC, Mehta AB, Walkey AJ. Practice patterns and outcomes associated with procalcitonin use in critically ill patients with sepsis. Clin Infect Dis. 2017;64:1509–15.CrossRefGoogle Scholar
  71. 71.
    Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39:2048–58.CrossRefGoogle Scholar
  72. 72.
    Andriolo BN, Andriolo RB, Salomao R, et al. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2017;1:CD010959.PubMedGoogle Scholar
  73. 73.
    Vincent JL, Teixeira L. Sepsis biomarkers: value and limitations. Am J Respir Crit Care Med. 2014;190:1081–2.CrossRefGoogle Scholar
  74. 74.
    Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11:R38.CrossRefGoogle Scholar
  75. 75.
    Gibot S, Bene MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med. 2012;186:65–71.CrossRefGoogle Scholar
  76. 76.
    Balk RA, Kadri SS, Cao Z, et al. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. Chest. 2017;151:23–33.CrossRefGoogle Scholar
  77. 77.
    Westwood M, Ramaekers B, Whiting P, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19:v–xxv. 1–236PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Intensive CareErasme Hospital, Université Libre de BruxellesBrusselsBelgium
  2. 2.Laboratoire de Médecine Expérimentale (ULB 222 Unit)Université Libre de Bruxelles, CHU de Charleroi, A. Vésale HospitalMontigny-Le-TilleulBelgium

Personalised recommendations